READ-ONLY DIGITIZATION RESULT
CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial.
Blood Adv · 2026-Apr-28 · PMID 41628350
Panel C提取完成待 EXE 对齐验证
OS
Figure 2. OS by genetic classification and treatment arm (CPX-351 vs 7+3). (A) OS in AML-MR by treatment. (B) OS in TP53 -AML by treatment arm. (C) OS in other-AML by treatment arm. (D) OS in DDX41 -AML by treatment arm. Time is measured from random assignment.
算法:legacy-0.5.0引擎:enhanced-linux
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | complete | 待验证 | 2 | 2026-07-18T19:10:43+00:00 |